The United Kingdom and the United States have forged a significant bilateral deal that will maintain zero duties on British drug exports being sold in the American market.
Agreement Details of the Pact
Under the terms of the agreement, the UK has pledged to boost funding on drugs through the National Health Service (NHS). This move ensures that import taxes on these vital products will stay at zero for a duration of 36 months.
This agreement comes after previous threats to hike import taxes on branded pharmaceutical products, with increases discussed as high as one hundred percent.
"This agreement with the Britain reinforces the global environment for cutting-edge drugs and establishes long-overdue equity to U.S.–U.K. pharmaceutical trade," a release said.
Economic Significance
Medicines are one of the UK's largest goods shipped to the US, which is clearly the largest destination for large British pharmaceutical firms.
Statistics reveal that in the year leading up to September, the UK sold pharmaceutical products valued at billions to the US. This amount represented nearly one-fifth of total UK exports in that timeframe.
"This guarantee secures employment, boosts investment and sets the stage for the UK to become a international leader for medical research," a minister commented.
Specific NHS Changes
The pact entails several key pledges from the United Kingdom:
- Higher Cost Ceiling: The UK will raise the cost ceiling at which it judges new therapies to be prohibitively costly by a quarter.
- Increased NHS Spending: There is a aim to increase overall health service expenditure on medicines from 0.3% of GDP to 0.6% over the coming ten years.
- Rebate Cap: The amount manufacturers must refund to the NHS to control costs will be capped at fifteen percent. In the past, repayments topped 20%.
Broader Context
The pact follows a long-running tension between the sector and the UK government over drug pricing and NHS adoption.
This friction were intensified by claims that American customers were charged a premium for the same drugs than people in the Britain and the EU.
Recently, several large drug company projects in the UK have been halted or cancelled, while substantial expansions have been directed toward American operations.
A senior figure acknowledged that the NHS must spend more on drugs, noting that its expenditure on drugs had shrunk as a proportion of its resources over the last ten years.
